Home » Stocks » PPD

PPD, Inc. (PPD)

Stock Price: $36.50 USD 0.56 (1.56%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $36.45 -0.05 (-0.14%) Jan 15, 6:58 PM
Market Cap 12.76B
Revenue (ttm) 4.36B
Net Income (ttm) 53.83M
Shares Out 348.67M
EPS (ttm) 0.16
PE Ratio 222.56
Forward PE 27.10
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $36.50
Previous Close $35.94
Change ($) 0.56
Change (%) 1.56%
Day's Open 35.78
Day's Range 35.41 - 36.56
Day's Volume 524,952
52-Week Range 14.00 - 37.00


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 weeks ago

PPD, Inc. (PPD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

InvestorPlace - 1 month ago

The year has seen more than 370 companies go public, so finding the 10 best IPOs to invest in won't be easy. Here are the top contenders.

Other stocks mentioned: AZEK, FEAC, IPOB, IPOC, JWS, LSF, PSTH, REYN, XPEV
24/7 Wall Street - 2 months ago

Most experienced investors are well aware of the major indexes that compose the equity markets.

Other stocks mentioned: DKNG, HZNP, NET, CDAY
Seeking Alpha - 2 months ago

PPD, Inc. (PPD) CEO David Simmons on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Investor sentiment remains strong for PPD, as shareholders have enjoyed almost 250% upside since the selloff in March. The stock has bounced away from support 7 times since then, in a narrow a...

Seeking Alpha - 2 months ago

HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.

Other stocks mentioned: ASLN, LGND, LLY
Zacks Investment Research - 3 months ago

PPD saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Business Wire - 4 months ago

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Pricing of Secondary Offering of Shares of Common Stock

Business Wire - 4 months ago

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Secondary Offering of Shares of Common Stock.

PRNewsWire - 4 months ago

LOS ANGELES, Aug. 20, 2020 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today announced it closed an oversubscribed $40 million funding round.

Seeking Alpha - 5 months ago

PPD beats the Street by $84.5 million on revenues, but misses EPS by $0.15.

Seeking Alpha - 5 months ago

PPD, Inc. (PPD) CEO David Simmons on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it has signed a new three-year agreement with Pfizer Inc. to provide...

InvestorPlace - 5 months ago

The Renaissance IPO Index is up 37.7% year to date compared to -1.3% for the S&P 500. Here are seven new stocks to buy from this index.

Other stocks mentioned: LVGO, REYN, RPRX, WMG, ZI
Seeking Alpha - 8 months ago

PPD's (PPD) CEO David Simmons on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

PPD (NASDAQ: PPD) shares are trading higher on Friday, after Morgan Stanley maintained an Overweight rating and raised its price target from $26 to $30.

Seeking Alpha - 11 months ago

PPD - Fully Valued Drug Development Company

24/7 Wall Street - 11 months ago

PPD Inc. (NASDAQ: PPD) made an exciting entrance to the market Thursday.

Market Watch - 11 months ago

PPD Inc. shares soared 14% in their trading debut Thursday, after the drug research company's initial public offering priced at the high end of its $24 to $27 price range.

About PPD

PPD provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central ... [Read more...]

Drug Manufacturers-Specialty & Generic
IPO Date
Feb 6, 2020
David S. Simmons
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, PPD, Inc.'s revenue was $4.03 billion, an increase of 7.52% compared to the previous year's $3.75 billion. Earnings were $47.82 million, a decrease of -54.10%.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for PPD, Inc. stock is "Strong Buy." The 12-month stock price forecast is 40.13, which is an increase of 9.95% from the latest price.

Price Target
(9.95% upside)
Analyst Consensus: Strong Buy